Table of Contents Table of Contents
Previous Page  457 / 1096 Next Page
Information
Show Menu
Previous Page 457 / 1096 Next Page
Page Background

S442

ESTRO 36

_______________________________________________________________________________________________

Conclusion

RapidPlan model evolves when the sub-optimal

constituent training sets were replaced by the improved

plans that were re-optimized by the model. One iteration

is most cost-effective.

PO-0823 Hierarchical constrained optimization for

automated SBRT paraspinal IMRT planning

M. Zarepisheh

1

, L. Hong

1

, J.G. Mechalakos

1

, M.A. Hunt

1

,

G.S. Mageras

1

, J.O. Deasy

1

1

Memorial Sloan Kettering, Medical Physics, New York,

United States Minor Outlying Island

Purpose or Objective

To develop a fully automated approach to IMRT treatment

planning using hierarchical constrained optimization and

the Eclipse API for SBRT paraspinal cases.

Material and Methods

This study formulates the IMRT treatment planning

problem as a hierarchical constrained optimization (HCO)

problem (also known as prioritized optimization). HCO

prioritizes the clinical goals and optimizes them in ordered

steps. In this study, we maximize tumor coverage first and

then minimize critical organ doses in the subsequent steps

based on their clinical priorities (e.g., (1) maximize tumor

coverage, (2) minimize cord or cauda dose, (3) minimize

esophagus dose,...). For each organ we define an

objective function, based on the gEUD concept, which

correlates with the clinical criterion. At each step, we

preserve the results obtained in the prior steps by treating

them as hard constraints with a slight relaxation or ”slip”

to provide space for subsequent improvement. Maximum

dose criteria to the tumor and other organs is always

respected through hard constraints applied at all steps.

To solve the resultant large-scale constrained

optimization problems, we use two commerical solvers,

knitro

and

ampl

. The Eclipse API is used to pull patient

data needed for optimization (e.g., beam geometries,

influence matrix). After solving the optimization

problems, the optimal fluence map is imported back to

Eclipse for leaf sequencing and final dose calculation using

the Eclipse API. The entire workflow is automated,

requiring user interaction solely to prepare the contours

and beam arrangement prior to launching the HCO Eclipse

API plugin. Optimization requires ~1-3 hours, after which

the automated plan including final dose calculation is

ready in Eclipse.

Results

HCO IMRT automatic planning was tested for 10 patients

with spinal lesions who had previously been treated to 24

Gy in a single fraction using either VMAT (8 patients) or

multi-field IMRT (2 patients). All automated HCO plans

used multi-field IMRT. A typical automated and clinical

plan comparison is shown in Figure 1, demonstrating

improved PTV coverage, cord and esophagus sparing with

the automated plan. As shown in Table 1, on average, the

automated plan improved PTV coverage (V95%) by 1%,

cord maximum dose by 2%, cord D0.35cc by 12%, cauda

maximum dose by 15%, and esophagus V18Gy by 100%. All

HCO plans met all clinical planning criteria.

Table-1.

Comparison of clinical and HCO automated plans

for ten patients. For each criterion, the better score is

bolded.

Figure-1.

Comparison of the clinical and automated plans

for a patient. A1-A3 represent the automated plan and C1-

C3 represent the clinical plan.

Conclusion

Hierarchical constrained optimization shows promise as a

powerful tool to automate IMRT treatment planning. The

automated treatment plan meets all clinical criteria and

compares favorably in relevant metrics to the plan

generated by planners. Using Eclipse API, we developed a

plugin which fully automates the workflow and can be

implemented into clinical use after thorough testing.

Poster: Physics track: Treatment planning: applications

PO-0824 IMRT dose painting for prostate cancer using

PSMA-PET/CT: a planning study based on histology

K. Koubar

1,2

, C. Zamboglou

2,3

, I. Sachpazidis

1,2

, R.

Wiehle

1,2

, S. Kirste

2,3

, V. Drendel

2,4

, M. Mix

2,5

, F.

Schiller

2,5

, P. Mavroidis

6,7

, P.T. Meyer

2,5

, A.L. Grosu

2,3

, D.

Baltas

1,2

1

Medical Center University of Freiburg - Faculty of

Medicine - University of Freiburg, Division of Medical

Physics - Department of Radiation Oncology, Freiburg,